Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib-Reference-Cited by-同舟云学术

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Published:2017-11-21 Issue:1 Volume:19 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Bagegni Nusayba,Thomas Shana,Liu Ning,Luo Jingqin,Hoog Jeremy,Northfelt Donald W.,Goetz Matthew P.,Forero Andres,Bergqvist Mattias,Karen Jakob,Neumüller Magnus,Suh Edward M.,Guo Zhanfang,Vij Kiran,Sanati Souzan,Ellis Matthew,Ma Cynthia X.

Funder

Pfizer Pharmaceutical

Susan G. Komen Promise Grant

Siteman Cancer Center Grant

Saint Louis Men's Group Against Cancer

NCI Cancer Clinical Investigator Team Leadership Award

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-017-0913-7.pdf

Reference35 articles.

1. Welin M, Kosinska U, Mikkelsen NE, Carnrot C, Zhu C, Wang L, Eriksson S, Munch-Petersen B, Eklund H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A. 2004;101(52):17970–5.